The PAWS Pet Company, Inc. Executes Agreement to

New Post Public Reply Private Reply Replies (0) Message Board
MicroCapStocksRock Rhythm Guitar #30232

The PAWS Pet Company, Inc. Executes Agreement to Acquire MESA Pharmacy, Inc. Orders expected to exceed $25 Million in 2014

Paws Pet Company, Inc. (QB) (USOTC AWS)
Intraday Stock Chart

Today : Tuesday 29 October 2013

Click Here for more Paws Pet Company, Inc. (QB) Charts.

The PAWS Pet Company, Inc. (OTCQB AWS), announced it has executed an agreement to acquire MESA Pharmacy, Inc. as part of its new strategy to become a dominant player in the delivery of compounded pharmaceutical products to consumers.

PALO ALTO, CA ,  Oct. 29, 2013 /PRNewswire/ - The PAWS Pet Company, Inc. (OTCQB AWS) has executed an agreement to acquire MESA Pharmacy, Inc. (MESA) from its parent, Pharmacy Development Corp. in exchange for preferred  stock . PAWS will be filing a report on Form 8-K within the next few days. Previously, the Company had announced that it and PDC had determined to enter into a joint venture, however progress on PDC/MESA's audit has been much better than anticipated and the parties have determined that purchasing MESA would be better for all of the parties and their respective  shareholders .

MESA focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and clinics. MESA has developed a series of topical ointments, in different strengths, that provide the pain relief doctors seek.

During the current month, according to MESA, it has received more than  $3,400,000 in orders and filled more than  $1,500,000 in actual prescriptions. MESA believes that it is on track to exceed  $25,000,000 in revenues during  fiscal year 2014 with much greater revenues a very real possibility.

PDC will be paid a royalty on collection for each prescription filled by MESA as well as receiving 500,000 shares of PAWS Series D Convertible Preferred Stock. The parties will begin the process of transferring MESA's license from PDC to PAWS as soon as possible and the  transaction is intended to close upon the issuance of a new  California pharmacy license or sooner. PDC has the right to appoint three members to the Board of Directors as soon as the new license is issued and the audit of MESA's operations is completed.

Furthermore, the holders of a majority of the Company's Series B Convertible  Preferred Stock shares have agreed to vote to reduce the maximum conversion rate in order to offset the new Series D stock, on a fully diluted basis.

Additionally, PAWS intends to spin off its remaining airline related properties, freeing the Company of much of its debt and further intends to settle most of its remaining debt in the very near future.

"We are excited about these developments, for our company and our shareholders, and we believe with MESA's great team, a great  foundation for future growth is set", said Dan Wiesel CEO of The PAWS Pet Company. He continued, "With the execution of this agreement, the way forward for PAWS is clear and we will now focus on completing the licensing process, domesticating the Company in  Nevada and changing our name to Praxsyn Corporation."

About The PAWS Pet Company, Inc.

The PAWS Pet Company, Inc. is undergoing a transition from the pet space to the pharmaceutical space. This exciting transition strategy has been developed to take advantage of the changes underway in traditional medical services. PAWS believes that great  opportunities exist in pharmaceuticals and how they are delivered to the public.

For more information on The PAWS Pet Company go to www.thepawspetcompany.com
For more  information on Pharmacy Development Inc. go to www.pharmacydevelopment.com
Company Contact: ir@thepawspetcompany.com

Forward-Looking Statements

Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.

SOURCE The PAWS Pet Company, Inc.

Copyright 2013 PR Newswire

My Favorite plays are on the Nasdaq DIP and RIP Board http://investorshangout.com/NASDAQ-DIP-and-RIP-87909/
My Favorite Paid chat room with amazing chart setups is The Trading Stock Lounge http://www.thetradingstocklounge.com/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ardelyx Securities Fraud Suit: Key Investor Moves

Updated Category News Views 5

Fraud Allegations: Ardelyx Under the Microscope Looks like Ardelyx has found itself neck-deep in trouble, facing a class action lawsuit over alleged securities fraud. This isn't just a storm in a teacup. We're talking about accusations of false and misleading statements tied to their commercial performance—statements that might have left investors holding the bag with...

Continue Reading
PrideStaff: 8 Years Strong on Franchise Times Top 400

Updated Category News Views 4

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Continue Reading
Steel Dynamics Gears Up for Q3 2026 Earnings Update

Updated Category News Views 6

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

Continue Reading
Newfold Digital Revamps Leadership for Growth Surge

Updated Category News Views 4

Steering into New Horizons with Fresh Leadership October 2026 marks a fresh chapter for Newfold Digital, as they shuffle the deck chairs a bit and ramp up for some ambitious growth endeavors. This web and commerce tech company decided it's time to bring a few heavy hitters on board. Starting this month, watch out for Sachin Puri taking the reins as Chief Executive...

Continue Reading
CME Group Unveils First Baseball Futures Market

Updated Category News Views 6

A New Pitch in the Financial Ballpark Alright, listen up: CME Group is stepping up to the plate with a game-changer. They’re rolling out the world’s first baseball futures, launching October 12, assuming regulators give the green light. Now, this isn’t just some novelty act; it’s based on the solid groundwork of their FutureSports Performance Indexes (CME FSPI),...

Continue Reading
Hexaware Teams with Anthropic for Game-Changing AI Move

Updated Category News Views 4

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...

Continue Reading
Protecting Your Family on Halloween: Safety Tips

Updated Category News Views 5

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

Continue Reading
Lupin Secures FDA Nod for Key Injectable Drug

Updated Category News Views 4

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...

Continue Reading
Webull Faces Legal Scrutiny Over Chinese Ties

Updated Category News Views 4

The Unfolding Drama for Webull Shareholders When you see a ticker like NASDAQ:BULL rolling off your tongue these days, it’s not just about stock prices anymore—it's a whole saga wrapped in legal and geopolitical spice. Following the recent uproar from a House China committee report, Webull found itself thrust into the spotlight for all the wrong reasons. That report...

Continue Reading
Striveworks: Boosting Army's AI Edge in Indo-Pacific

Updated Category News Views 6

The world keeps marching forward, and here’s Striveworks stepping up to the plate with another big move in the military tech space. This isn't your average partnership renewal; this involves a five-year, $200 million deal to enhance battlefield AI as the U.S. Army hones its modern warfare edge in the Indo-Pacific. Now, this isn't just a battle of strategies but a battle...

Continue Reading

Top 5 Most Recently Viewed Articles

Medpace Holdings Achieves Impressive Revenue Growth Despite Challenges

Updated Category News Views 187

Medpace Holdings Reports Strong Financial Growth Medpace Holdings, Inc. (NASDAQ: MEDP), a prominent provider of clinical research services, has recently demonstrated impressive financial performance with an 8.3% revenue increase year-over-year, totaling $533.3 million in the third quarter. Net income also surged by 36.7%, reaching $96.4 million. This positive growth comes...

Continue Reading
ECARX Launches Ambitious $20M Share Buyback Initiative

Updated Category News Views 118

ECARX Unveils $20 Million Share Repurchase Plan ECARX Holdings, Inc. (Nasdaq: ECX) is taking a significant step in its financial strategy by launching a share repurchase program valued at up to $20 million. This development indicates the company's commitment to returning value to shareholders while optimizing its capital structure. Details of the Share Repurchase Program...

Continue Reading
Abpro Holdings Marks Major Milestone with Successful IPO Ceremony

Updated Category News Views 163

Abpro Holdings Celebrates Its Successful Business Combination Abpro Holdings, Inc. (Nasdaq:ABP) is excited to announce the completion of its business combination with Atlantic Coastal Acquisition Corp II. A grand bell ringing ceremony at Nasdaq marked this significant achievement, highlighting the dedication and hard work Abpro has put into this journey. Through this...

Continue Reading
Navigating Securities Losses: A Look at Compass Diversified

Updated Category News Views 169

Understanding Your Rights as an Investor Investors in Compass Diversified Holdings (NYSE: CODI) facing substantial losses have a critical opportunity to take action. Many investors find themselves in challenging positions when companies fail to disclose critical financial information. Such scenarios can lead to significant investment losses. Understanding one's rights and...

Continue Reading
Exploring Future Growth in the Blood Glucose Monitoring Market

Updated Category News Views 247

The Rising Demand for Blood Glucose Monitoring Devices As health awareness increases and diabetes continues to affect millions globally, the Blood Glucose Monitoring Device market is set to experience remarkable expansion. Valued at USD 13.49 billion in recent times, this industry is anticipated to grow significantly, reaching around USD 27.61 billion by 2032. This...

Continue Reading